Comments on "Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome"

Affiliations

¹ Research and Development, Zealand Pharma A/S, Sydmarken 11, 2860 Søborg, Denmark JSkarbaliene@zealandpharma.com.
² Research and Development, Zealand Pharma A/S, Sydmarken 11, 2860 Søborg, Denmark.

Comment

Jolanta Skarbaliene et al. J Pharmacol Exp Ther. 2021 Jun.

. 2021 Jun;377(3):369.

doi: 10.1124/jpet.120.000426.

¹ Research and Development, Zealand Pharma A/S, Sydmarken 11, 2860 Søborg, Denmark JSkarbaliene@zealandpharma.com.
² Research and Development, Zealand Pharma A/S, Sydmarken 11, 2860 Søborg, Denmark.

Erratum in

Correction to "Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome".
[No authors listed] [No authors listed] J Pharmacol Exp Ther. 2021 Jun;377(3):368. doi: 10.1124/jpet.119.262238err. J Pharmacol Exp Ther. 2021. PMID: 34039656 No abstract available.

No abstract available

Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.
Hargrove DM, Alagarsamy S, Croston G, Laporte R, Qi S, Srinivasan K, Sueiras-Diaz J, Wiśniewski K, Hartwig J, Lu M, Posch AP, Wiśniewska H, Schteingart CD, Rivière PJ, Dimitriadou V. Hargrove DM, et al. J Pharmacol Exp Ther. 2020 May;373(2):193-203. doi: 10.1124/jpet.119.262238. Epub 2020 Feb 19. J Pharmacol Exp Ther. 2020. PMID: 32075870